GlassScriptPhysician profile
Allison Ann Sopko
NPI 1922442615
$1,181.65
in general payments reported to CMS, 2019-2025
20 companies · $287 in 2025
The $287 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $63.73 · 2021: $207 · 2022: $199 · 2023: $75.41 · 2024: $246 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $185.52 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $140.91 | 2019-2025 | Doc Band |
| Alk-Abello, INC | $106.98 | 2024-2025 | Odactra, Ragwitek, Grastek |
| Kaleo, INC. | $96.14 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $89.27 | 2019-2022 | |
| Tris Pharma INC | $85.80 | 2021-2024 | Dyanavel Xr |
| Cumberland Pharmaceuticals, INC. | $78.37 | 2024-2025 | Kristalose |
| Corium, LLC | $63.72 | 2024-2025 | Azstarys |
| Glaxosmithkline, LLC. | $60.60 | 2021-2025 | Bexsero |
| Seqirus USA INC | $51.00 | 2022-2024 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $43.99 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $32.24 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $29.34 | 2021 | |
| Becton, Dickinson and Company | $21.35 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.48 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $18.25 | 2025 | Neffy |
| Neos Therapeutics, LP | $15.89 | 2024 | Cotempla Xr-Odt |
| Astrazeneca Pharmaceuticals LP | $15.38 | 2023 | Flumist Quadrivalent |
| Ironshore Pharmaceuticals INC. | $14.75 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Sopko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.